Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: Results of a SFGM-TC randomised trial

Bone Marrow Transplantation

Volumn 36, Issue 6, 2005, Pages 547-552

  Valteau Couanet, D ^a   Faucher, C ^b   Auperin A ^a   Michon, J ^c   Milpied, N ^d   Boiron, J M ^e   Bourhis, J H ^a   Gisselbrecht, C ^f   Vernant, J P ^g   Pinna, A ^a   Bendahmane, B ^h   Delabarre, F ^h   Benhamou, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INSTITUT CURIE   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SANOFI   (France)

Author keywords

Autologous PBSC transplantation; Cost effectiveness; G CSF; Randomised study

Indexed keywords

ANTIINFECTIVE AGENT; BUSULFAN; CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; FEMALE; FEVER; FOLLOW UP; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKAPHERESIS; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; BUSULFAN; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 31044442838     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705097     Document Type: Article

References (13)

1. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607.
2. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
3. Bolwell B, Goormastic M, Dannley R et al. G-CSF post-autologous progenitor cell transplantation: A randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19: 215-219.
4. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
5. Faucher C, Le Corroller AG, Chabannon C et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: The number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663-670.
6. Schmitz N, Ljungman P, Cordonnier C et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: Results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955-962.
7. Hornedo J, Sola C, Solano C et al. Multicentric prospective, randomized study of the role of filgrastim (G-CSF) after transplant of hematopoietic progenitor cells mobilized with G-CSF in patients with cancer of the breast. Sangre (Barc) 1997; 42 (Suppl. 1): 54-56.
8. Linch DC, Milligan DW, Winfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial. Br J Haematol 1997; 99: 933-938.
9. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
10. Kawano Y, Takaue Y, Mimaya J et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 1998; 92: 4040-4046.
11. Ojeda E, Garcia-Bustos J, Aguado M et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24: 601-607.
12. Lee SM, Radford JA, Dobson L et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: Clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294-1299.
13. Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: A randomized study. Bone Marrow Transplant 1996; 17: 533-536.